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Abstract 
Oxolinic acid (OXO) has been routinely used in aquaculture as both 
prophylactic and chemotherapeutic agents, principally against systemic 
bacterial infections. The residue depletion of OXO was investigated in cobia 
following multiple (5 days) in-feed dosing (30 and 60 mg/kg body 
weight/day) at 25°C; we assessed OXO concentrations of liver and muscle 
(+skin) samples post-treatment for three weeks. The OXO residues were 
quantified using a validated ultra-high-performance liquid chromatography-
tandem mass spectrometry (UPLC-MS/MS) method and the results indicated 
recoveries of 86.6-95.8%, with relative standard deviations (RSD) less than 
8.5% for intra- and inter-day precisions. Within the range of 10−500 ng/g, the 
calibration curves for all matrices presented a determination coefficient 
greater than 0.99. Limit of detection and quantification were estimated at 6 
and 10 ng/g, respectively. In order to account for the high variability of the 
residue data, a safety span corresponding to 50% of depletion time could be 
seen as appropriate. Considering a maximum residue limit (MRL) of 50 ng/g 
established by the Taiwan FDA for OXO in muscle with skin in natural 
proportions, a withdrawal period of 15 days was calculated for the sum of 10-
day depletion time and 5-day safety span. These results revealed that the 
analytical method is developed for residue OXO and that the withdrawal 
period is appropriate.  
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Introduction 
Aquaculture production is one of the most relevant sources of food protein production 
worldwide. Cobia (Rachycentron canadum), have aroused high interest in the aquaculture 
sector and scientific community, and are an emerging species for marine aquaculture 
from the Indo-Pacific waters to the southern Atlantic Ocean. Due to its favorable 
characteristics such as excellent meat quality, rapid weight gain, and easy spawning in 
captivity, in both domestic and international markets, technology for its culture has 
rapidly developed, including mass propagation, natural spawning of captive brood stocks, 
larval rearing techniques, nursery production in tanks, in open ponds, near shore and 
offshore cages in Taiwan (Liao et al., 2004). However, aquatic animal diseases have 
become a major constraint inhibiting their aquaculture production. The major infectious 
diseases affecting cobia include bacterial (pasteurellosis, vibriosis and streptococcosis), 
parasitic myxosporidea, Trichodina, Neobenedenia and Amyloodinium infestations, and 
viral lymphocystis (Liao et al., 2004). It is therefore important that therapeutic regimens 
are designed to maximize efficacy and minimize the risk of the development of resistant 
pathogens. 
The benefit of improved productivity of veterinary drugs in comestible animals is 
often associated with the risk with drug residues in the tissues of treated animals at the 
time of slaughter or residues due to improper drug usage and failure to keep the 
withdrawal period. Thereby there is a legal requirement that drug concentrations do not 
persist at a level greater than those established as safe by the relevant regulatory 
authority in the country of origin (Beyene, 2016). The highest level is referred to as the 
maximum residue level (MRL), that is legally tolerated in food of animal 
origin when veterinary drugs are applied correctly. 
Many of the countries involved in aquaculture have established mechanisms for 
veterinary drug approval and monitoring process in aquaculture. The European Medicine 
Agency (EMA) regulates the licensing and authorization of drug usage in aquaculture for 
countries under EU. The Codex Alimentarius Commission (CAC) is a joint FAO/WHO 
commission charged with developing standards for food safety with worldwide 
applications. In Taiwan the application of drugs in aquaculture is regulated by the 
‘Bureau of Animal and Plant Health Inspection and Quarantine (BAPHIQ)’ to ensure safe 
and effective drugs/medicines for use in aquaculture. 
Quinolones such as oxolinic acid (OXO), have a wide bioavailability, relative low 
toxicity, and favorable pharmacokinetics, and have been extensively used in aquaculture 
against bacterial infections including pasteurellosis, vibriosis and streptococcosis, etc. 
(Sellyei et al., 2009; Touraki et al., 2012; Dangwetngam et al., 2016), by increasing the 
concentration of drug-enzyme-DNA cleavage complexes and converting them into cellular 
toxins to turn them into bactericidals (Naeem et al., 2016). OXO is authorized in 
veterinary medicine for use in fin fish. The recommended doses are 12 mg/kg bw/day for 
up to 7 days for the treatment of gastro-enteritis due to Escherichia coli as set by 
European Medicines Agency (EMA) (2005). Permitted limits, MRL, of OXO are 100 ng/g 
allowed by the European Union (EU) established for muscle and skin in natural 
proportions (EU, 2009). 
Though a number of residue studies for OXO have been published (Samuelsen et al., 
1992; Guo and Liao, 1994; Rigos et al., 2003; Gonzalez et al., 2010), no previous work 
has investigated Cobia (R. canadum). This study was undertaken to establish the 
withdrawal time following OXO treatments of cultured cobia to depletion below 50 ng/g in 
muscle and skin (the current tolerance level set by the Taiwan Food and Drug 
Administration (Taiwan FDA; TFDA) (TFDA, 2014). An effort was made to standardize the 
administration of the drug as well as the sampling and analytical protocol. The results 
obtained from these drug depletion trials suggest that public policies should impose 
regulations to ensure the proper use of OXO in cobia farms to further protect the health 
of consumers and maintain high export safety. 
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Materials and Methods 
Animal management. 
Healthy cobia (mean weight, 140-170 g) obtained from Fanliao aquafarms, (Pingtung, 
Taiwan), had been maintained at 25°C in fiber-glass-reinforced plastic (FRP) tanks of 1.8 
ton (1.2 × 2.0 × 0.75 m) capacity with flow-through water systems during the 
experiments (Fig. 1). Fish were fed either medicated or nonmedicated commercial feed at 
the rate of 1% of fish body weight once each day in the morning. All animal studies were 
performed according to the protocols approved by the Institutional Animal Care and Use 
Committee at National Taiwan University (103-EL-20) and were carried out in accordance 
with the provisions of the EC Council Directive 2010/63/EU. Before the onset of drug 
administration, the cobia were acclimated for at least 2 weeks during which they were 
fed antibiotic-free commercial feed. 
 
Fig. 1. Fiber-glass-reinforced plastics tank used for fish farming in residue depletion study. 
 
Study design. 
Medicated and unmedicated feed products (Oxalyl powder®) were obtained from 
Juily Pharmaceutical Co., LTD (New Taipei City, Taiwan). Animals in the control group (no 
OXO added) were processed simultaneously. The OXO antibiotics concentration in feed 
was calculated to obtain an intake equivalent to a dose of 30 or 60 mg/kg of body 
weight. All medicated feeds were provided for 5 days. The low dose of 30 mg/kg/day was 
selected based on empirical, positive impressions of clinical efficacy in aquatic species. 
The high dose of 60 mg/kg/day was chosen to monitor safety at the 2 dose levels within 
the trial. In this study, the experimental protocol included the sampling of fish at 1, 3, 5, 
7, 10, 14 and 21 days after the 5-d medication period. Five fish were randomly sampled 
at each time point and sacrificed to analyze the residues of OXO in selected tissues (liver 
and muscle-skin samples). Muscle and the overlying skin were dissected from the mid-
trunk region near the lateral line. The sampled area was descaled prior to excision from 
the fish and were kept frozen at -20°C until being analyzed. 
Sample preparation. 
Antimicrobials were extracted from aquatic tissue using an extraction procedure 
based on less organic solvent consuming methodology. A 5 g homogenate fish sample 
(muscle-skin/liver) was mixed with 25 mL of acetonitrile containing a 5% of methanol, 
and homogenized with a 12-speed osterizer blender (Oster, US) for 3 min. Then 10 g of 
anhydrous sodium sulfate (Na2SO4) was added, and the mixture was shaken using a Cute 
Mixer (CM-1000; Eyela, Japan) for 10 min and centrifuged (5804R, Eppendorf, Germany) 
at 3,500 xg, for 10 min at 4°C. The supernatant was then transferred into a clean tube. 
The extraction procedure was performed twice; then the two extracts were combined and 
transferred into a separatory funnel and 30 mL of n-hexane saturated with acetonitrile 
was added to the solution and the contents were shaken vigorously for 3 min in a 
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reciprocating shaker. The acetonitrile layer was then transferred to a vacuum rotary 
evaporator flask, and concentrated to dryness at 40°C. Finally, the residue was 
redissolved in methanol (50%) to make exactly 1 mL of sample solution, and this was 
filtered through a 0.22 µm nylon membrane filter, followed by LC-MS/MS analysis. 
Determination of OXO residues in cobia by qualitative LC-MS/MS. 
The chromatographic analyses were performed on an Acquity UPLC system, and 
separations were achieved using an Acquity UPLC® HSS C18 column (1.7 m, 2.1  100 
mm; Waters, US). The column temperature was set at 35°C. The mobile phase flow rate 
was fixed at 0.2 mL/min and the following program was applied for the elution:  
0 min, 96% A; 0−2 min, 96-95% A; 3.0−6.0 min, 80−75% A; 6.0−8.6 min, 75−73% A; 
8.6−14.5 min, 73−63% A; 14.5−14.7 min, 63−0% A; 14.7−18.7 min, 0−96% A and 
18.7−20.0 min, 96% A. Deionized water (DI water):formic acid (99.9:0.1, v/v) as eluent 
A and methanol: formic acid (99.9:0.1, v/v) as solvent B. Injection volume was 10 L. 
Mass spectrometry analyses were carried out using a Waters Acquity TQS™ Micromass 
Quattro Ultima triple-quadrupole MS quadrupole equipped with an electrospray ion 
source (Micromass, Manchester, UK). The instrument was operated using an electrospray 
(ESI) source in positive mode with the following parameters: 3.3 kV capillary voltage, 25 
V cone voltage, 120°C source temperature, 450°C desolvation temperature, 100 L/h 
cone gas flow and 800 L/h desolvation gas. The OXO isomers were fragmented using 
collision-induced dissociation and the multiple reaction monitoring (MRM) transitions m/z 
= 262 > 244, m/z = 262 > 216 and m/z = 262 > 160 were monitored (m/z, mass-to-
charge ratio). Data acquisition was performed using MassLynx V 4.1 software with the 
Quanlynx program (Waters). 
Quality control. 
The method was validated with the following performance parameters: linearity and 
linear range, detection and quantitation limits. The intra-day and inter-day precision of 
the method, expressed as the relative standard deviation (RSD) of known concentrations 
measurements, were assessed by using blank fish samples fortified with OXO at three 
concentrations of 10, 50, and 100 ng/g. Five replicates determination of each 
concentration was conducted during routine operation of the system over a period of five 
consecutive days. Internal quality controls were used, e.g., a blank extract was used to 
identify false positive results obtained through contamination from the extraction 
process, instruments, or chemicals, and to identify possible matrix interferences. Another 
blank sample was spiked with OXO at 10 ng/g (muscle) and 20 ng/g (liver) and the 
extraction efficiencies were assessed. A matrix-matched calibration curve was prepared 
daily from the blank matrix extract. 
Results 
Methods validation 
The developed procedure was designed to obtain qualitative and quantitative surveillance 
information about the quinolone antibiotic and to simultaneously analyze the same 
analytical protocol. The identification of OXO by LC-ESI-MS/MS obtained from fortified 
blank fish muscle-skin and liver samples with retention times ranging from 18.302 to 
18.363 minutes. Linear regression coefficients (R(2)) of matrix-match calibration 
standard curves established for quantification were higher than 0.9989, which is 
adequate for analytical purposes. Inter-assay precision with percentage relative standard 
deviations (RSD) was in the range 2.3-8.5%. Intra-day precision (RSD) was lower than 
5.6%. The limit of detection (LOD) was 6 ng/g given by signal-noise ratio ≥ 3 (S/N) and 
the limit of quantification (LOQ, S/N ≥ 10) was estimated at 10 ng/g. Average recoveries 
and extraction efficiency were synonyms of the fortified OXO at two concentrations 10 
and 20 ng/g were between 86.6% and 95.8%, with RSD in the range of 1.4-4.2%. 
Residue depletion studies 
In the 5-day repeated dose study in cobia, OXO was performed using doses of 30 
and 60 mg/kg bw/day in the low- and high-dose groups. Results for OXO depletion from 
fish tissues (muscle plus skin in natural proportions and liver) at different times are 
shown in Table 1. The OXO concentrations were below the MRL (50 ng/g) established by 
the Taiwan FDA: range 30-40 ng/g in the muscles (at day 5), and 10-30 ng/g in the liver 
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(at day 5), respectively, for cobia in the low-dose groups; whereas range 10-30 ng/g in 
the muscles (at day 7), and 20-30 ng/g in liver (at day 10), respectively, in the high-
dose groups. 
Table 1. Oxolinic acid depletion at different times in cobia tissues. 
Time  dose group)-(low 1OXO concn (ng/g)   OXO concn (ng/g) (high-dose group) 
2day   Control Muscle + skin Liver  Control Muscle + skin Liver 
1  3 ND 62  11.7 64  20.6  ND 202  44.5 264  95.4 
3  ND 44  20.6 50  11.0  ND 170  23.7 33  10.9 
5  ND 34  4.9 18  7.5  ND 72  11.7 42  14.7 
7  ND 16  4.9 12  4.0  ND 22  7.5 40  11.0 
10  ND ND ND  ND 34  8.0 24  4.9 
14  ND ND ND  ND 6.0  4.9 20  0.0 
21  ND ND ND  ND ND ND 
1 Values are means  SDs for 5 samples. 
2 Day after the last administration of medicated food. 
3 Not determined. 
 
Discussion 
The results in this work show that OXO bioacumulate at high concentrations in the 
muscle and liver, even though in the liver samples the concentrations fell below the MRL. 
In addition, the depletion time results agree with those reported by other researchers for 
depletion behavior of OXO in different species. In the case of a single oral dose of 40 
mg/kg of OXO in orange-spotted grouper E. coioides, Guo and Liao (1994), found the 
elimination half-life (t1/2) value of 15.1 h at 24 °C, and OXO absorption was complete in 
about 12 h following dosing as well as the highest concentrations were measured in the 
kidney followed by the liver, muscle and serum; afterward, its concentrations declined 
below the MRL 10 days following medication. 
Furthermore, another study showed that following OXO multiple medications of 25 
mg/kg/day to salmon (Salmo salar L.) for ten days at 9°C, depletion times after 
treatment ceased for the residues of OXO concentrations  which fell below the MRL of 50 
ng/g after 12 days in the liver, followed by the muscle and plasma (Samuelsen et al. 
1992). Similarly, another study found that the distribution and elimination of OXO in 
gilthead sea bream (S. aurata) and sharpsnout sea bream (D. puntazzo) following oral 
administration of 30 mg/kg/day on ten consecutive days at 19°C (Rigos et al., 2003). 
Elimination t1/2 were estimated to be 11-14 and 11-19 h in tissues of gilthead sea bream 
and sharpsnout sea bream, respectively. OXO concentration in sparids peaked on day 4, 
with highest concentrations in liver, followed by bile, skin, muscle and plasma, where its 
concentrations diminished 12 days after ceasing treatment. 
As for differences in tissue distributions, it is known that biological factors affecting 
drug distribution are blood flow to tissue and capillary porosity (Sim, 2015). Drugs 
rapidly enter high perfused tissues with discontinuous capillaries (e.g. liver), while drug 
distribution into the tissues with low perfusion rates and with continuous capillaries (e.g. 
skin) is slow (Hamamoto and Mizuno, 2017). Higher OXO concentrations in muscle-skin 
samples than those in liver samples at the withdrawal period in the present study seem 
to be caused by slow drug transfer between muscle, skin, and plasma depending on the 
low blood perfusion in cobia muscle and skin. 
Since marketing authorization applications for veterinary medicinal products for use 
in food producing species must include an indication of the withdrawal period, it is 
recommended to determine withdrawal period at the time point where the concentrations 
of residues in edible tissues fall below the respective MRL (EMA, 2018) for muscle and 
liver samples (50 ng/g). Also, the estimation of a safety span should be calculated from a 
half of tissue depletion time. Therefore, in order to account for the high variability of the 
residue data, this safety span corresponds to 50% of the 10-day depletion time; the 
conclusive approach would then result in a withdrawal period of 15 days as in the present 
study. 
Our results agree with the general trend described by the aforementioned works, as 
on day 7 after treatment we found residue concentrations of 22  7.5 ng/g in cobia 
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muscle-skin samples, whereas in livers (at higher doses) these were of 24  4.9 ng/g. 
Concentrations declined and fell below the MRL on day 10 following the last 
administration. It can be assumed that warmwater fish are likely to process drugs faster 
than coldwater species. Higher ambient temperatures and/or salinity may increase 
xenobiotic metabolism and elimination rates (Gonzalez et al., 2010), for example, OXO 
has been shown to be eliminated much faster in fish in seawater than those in fresh 
water (Ishida, 1992). 
In conclusion, the analytical method for residual OXO in cobia liver and muscle was 
presented in our study. Our results determined by analytical methods prove that the 10-
day depletion period in cobia administered medicated feed at the maximum dose and 
administration period of OXO (60 mg/kg/day for 5-day) is appropriate to ensure that 
OXO concentrations are below the MRL (50 ng/g). The depletion behavior we have 
detailed in this work provides data supporting more prudent use of OXO in cobia and 
suggests a possible withdrawal period of 15 days (10-day depletion time + 5-day safety 
span) after treatment. It therefore aids in the design and application of new policies of 
antimicrobial surveillance. 
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